Patents Assigned to HYLORIS DEVELOPMENTS S.A.
  • Metolazone emulsion formulation
    Patent number: 12121520
    Abstract: The present invention relates to pharmaceutical formulations comprising metolazone, a lipid, and an emulsifier that provide a lipid formulation of metolazone that can be administered intravenously to patients, thereby enhancing the therapeutic delivery and improving patient care for acute heart failure and resistant edmitious states.
    Type: Grant
    Filed: July 18, 2022
    Date of Patent: October 22, 2024
    Assignee: Hyloris Developments S.A.
    Inventor: Somberg John
  • Method of initiating or escalating dofetilide dose and formulations therefor
    Patent number: 11957648
    Abstract: The present invention provides a novel method of initiating or escalating dofetilide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: April 16, 2024
    Assignee: HYLORIS DEVELOPMENTS S.A.
    Inventor: John Somberg
  • Metolazone emulsion formulation
    Patent number: 11389451
    Abstract: The present invention relates to pharmaceutical formulations comprising metolazone, a lipid, and an emulsifier that provide a lipid formulation of metolazone that can be administered intravenously to patients, thereby enhancing the therapeutic delivery and improving patient care for acute heart failure and resistant edmitious states.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: July 19, 2022
    Assignee: HYLORIS DEVELOPMENTS S.A.
    Inventor: Somberg John